Next Phase Newsletter

A publicly NASDAQ-traded diagnostics company with operations in China and the United States specializes in pre-cancer and cancer screening based on biophysical properties. The firm is looking to partner or acquire a majority share in early stage companies in the diagnostics space. While the firm is looking to be the majority stakeholder in these companies, the firm is most interested in continuing a partnership/joint venture with these startups, as opposed to a full acquisition. The firm is willing to partner globally.

The firm is interested in diagnostics companies only. Within diagnostics, the firm is interested in two types of partnerships. First, the firm is seeking oncology diagnostics that use genetic or biomarker identification of specific cancer types that can be paired with their technology, meshing the specific genetic/biomarker for these cancers with the biophysical anomalies they detect. Additionally, the firm is also looking to partner with companies in the oncology space that are seeking to expand to China and can take advantage of the firm’s existing infrastructure. For these partnerships, the firm is interested in all forms of diagnostics in all indications.

The firm is looking to acquire at least a 51% stake in the companies with which they are partnering, but is open to any structures that are advantageous for all parties. As a partner, the firm has facilities in place for any additional research or clinical tests needed to help companies reach commercialization in the United States, as well as the ability to help with distribution, especially in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare , including AI in healthcare and medical devices.

The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies.

The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed and pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Western Europe based venture capital firm provides university spin-offs as well as other promising start-up companies with capital, coaching and networks. The firm is an advisor to multiple funds, and is investing in a variety of technological industries; about 50% of the portfolio is in the life science sector. The firm makes allocations from $500,000 to $10M over the life of the investment, and in the life science sector allocations are typically over $5m. The firm primarily invests in companies based in Europe or with ties to Europe. Allocations to US, Canada and Israel are possible.

The firm invests in the biotech and medtech sectors and is opportunistic within these sectors regarding indication area and technology. The firm prefers to invest in early-stage companies, with assets ranging from preclinical to mid-stage clinical trials (Phase II for therapeutics).

The firm seeks highly qualified, ambitious management teams, and is typically an activist investor that takes a seat on a portfolio company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a large company is a stage-agnostic investor, and makes investments from Series B to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $5-10 million with the possibility of follow-on investments up to $20 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four areas of innovation in healthcare; pharma services, data and analytics, digital supply chain, consumer health, value based care. The firm is focused on financial returns in addition to how the firm can potentially contribute value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An angel investing firm founded in 2017 is based in San Francisco with easy access to Silicon Valley. Since January 2017, the firm has invested in several life sciences companies and continues to actively

invest. Typical size of investment ranges from $25-75K, and the firm provides strategic advisory and resources in addition to capital. The firm is open to considering investments from all across the globe.

The angel group is most interested in consumer-facing medtech and digital health technologies, especially those with a user experience design element that enables patient empowerment. The firm is primarily open to investing in Class 1 and 2 medical devices (e.g. SaMD and 510K) and generally avoids Class 3/PMA programs. The firm’s current portfolio includes a monitoring system for pediatric asthma, a wearable for measuring continuous blood pressure, a patient journey support service for cancer patients, an extended duration urinary catheter, etc. In general, the firm does not invest in physician tools, surgical devices or biopharma therapeutics with the occasional exception of areas in which the firm principal has expertise, including respiratory drug delivery, COPD, and diabetes.

The angel group seeks to work with motivated and passionate management teams developing novel products in the life sciences space. Most importantly, the firm seeks to work with companies where the firm could be of most value and becomes actively involved in helping their portfolio companies grow. That said, the firm does not necessarily seek board representation. An important additional discriminating factor is the perceived integrity and humility of the key executives.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The fund is looking for innovative and transformative therapeutics focused on preclinical drug development. The firm is a subsidiary of a foundation, which it can leverage the team at the foundation for venture and investment services, as well as operational support. The firm’s goal is to shepherd promising drug candidates through the riskiest, early stages of development. The firm will help its portfolio companies with experienced management, scientists, consultants, and investors.

The fund is interested in early-stage bioscience and therapeutics area including Autoimmune diseases and Immunology, Biofuels, Cancer, Cardiovascular Research, Glycobiology and Carbohydrates, Infectious Disease and Microbiology, Natural Products for Health, Vision Research. The firm is interested in companies in in development to pre-clinical stage.

The fund has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.